Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561546 | 0.79 | ALDH1A1 (0.53) | ALDH1A1RXFP1KDM4E | |
| SCHEMBL237122 | 0.79 | ALDH1A1 (0.53) | ALDH1A1RXFP1KDM4E | |
| SCHEMBL539008 | 0.79 | KDM4E (0.53) | KDM4ETYRO3DYRK1B | |
| SCHEMBL15718880 | 0.76 | KDM4E (0.37) | KDM4ETYRO3DYRK1B | |
| SCHEMBL1551964 | 0.76 | PDK2 (0.36) | ALDH1A1KDM4ETYRO3DYRK1B | |
| SCHEMBL5034214 | 0.76 | ALDH1A1 (0.50) | ALDH1A1RXFP1MAPKAPK2 | |
| SCHEMBL2934833 | 0.76 | ALDH1A1 (0.50) | ALDH1A1RXFP1FGFR1MAP3K14MAPKAPK2 | |
| SCHEMBL8447336 | 0.76 | ALDH1A1 (0.50) | ALDH1A1RXFP1FGFR1MAP3K14KDM4E | |
| SCHEMBL27657809 | 0.76 | ALDH1A1 (0.50) | ALDH1A1RXFP1FGFR1SRCDHFR | |
| SCHEMBL28016408 | 0.76 | ALDH1A1 (0.50) | ALDH1A1RXFP1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749255-A | A kind of preparation method of antiviral medicinal entecavir intermediate | 青岛辰达生物科技有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-1544434-A | 6-benzylaminopurine production process | 宝应县润扬化工有限公司 | 2004-11-10 | — | — | CN | claimed |
| US-6093819-A | Preparation of penciclovir or famciclovir | SMITHKLINE BEECHAM PLC (GB) | 2000-07-25 | — | — | US | claimed |
| JP-10218880-A | — | — | None | — | — | JP | disclosed |
| JP-6116266-A | — | — | None | — | — | JP | disclosed |
| JP-9188681-A | — | — | None | — | — | JP | disclosed |
| EP-4658280-A2 | SIX MEMBERED RING CONTAINING OLIGOMERS | Alnylam Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12173023-B2 | Crosslinked nucleoside intermediate crystal and method for producing same, and method for producing crosslinked nucleoside amidite | YAMASA CORPORATION (JP) | 2024-12-24 | — | — | US | disclosed |
| CN-113924308-B | Crystal of crosslinked nucleoside intermediate, process for producing the same, and process for producing crosslinked nucleoside phosphoramidite | 雅玛山酱油株式会社 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024163762-A2 | SIX MEMBERED RING CONTAINING OLIGOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20220315617-A1 | Crosslinked Nucleoside Intermediate Crystal And Method For Producing Same, And Method For Producing Crosslinked Nucleoside Amidite | YAMASA CORPORATION (JP) | 2022-10-06 | — | — | US | disclosed |
| US-20010010915-A1 | Methods and compositions pertaining to PD-Loops | TRUSTEES OF BOSTON UNIVERSITY | 2001-08-02 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| WO-2000008025-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| US-5917042-A | Process for the preparation of 2,5-diamino-4,6-dichloropyrimidine | GLAXO WELLCOME INC. (US) | 1999-06-29 | — | — | US | disclosed |
| JP-H10218880-A | PRODUCTION 2-AMINOPURINE DERIVATIVE | SUMIKA FINE CHEM KK | 1998-08-18 | — | — | JP | disclosed |
| JP-H09188681-A | 2-AMINO-6-CHLOROPURINE AND ITS PRODUCTION | SUMIKA FINE CHEM KK | 1997-07-22 | — | — | JP | disclosed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| JP-H06116266-A | PRODUCTION OF 2-AMINO-6-ALKOXYPURINE | NIPPON KAYAKU CO LTD | 1994-04-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315617-A1 | Crosslinked Nucleoside Intermediate Crystal And Method For Producing Same, And Method For Producing Crosslinked Nucleoside Amidite | PNP, ATIC, UMPS | ALDH1A1 1352/4885RXFP1 2225/4885DPP4 2743/4885 |
| US-12173023-B2 | Crosslinked nucleoside intermediate crystal and method for producing same, and method for producing crosslinked nucleoside amidite | PNP, ATIC, UMPS | ALDH1A1 1352/4885RXFP1 2225/4885DPP4 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.